DXCM
Dexcom IncCompany with tickers: DXCM
CIK
1093557
CUSIP
252131107
Shares Outstanding
385,872,977
Website
https://www.dexcom.com
Investor Relations
https://investors.dexcom.com/overview/default.aspx
13F Activity (30d)
53 filings
10 filers
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$750,000,000
as of 2025-04-30
Remaining Authorization
$142,300,000
as of 2023-06-30
· not restated in filings since 2023-10-26
Program Utilization
81.0%
$607,700,000 used of $750,000,000
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2025-12-31 | $500,000,000 | 10-K, filed 2026-02-12 | ||
| 2024-12-31 | $750,000,000 | 10-K, filed 2026-02-12 | ||
| 2023-12-31 | $688,700,000 | 10-K, filed 2026-02-12 | ||
| 2022-12-31 | $557,700,000 | 10-K, filed 2025-02-18 | ||
| 2021-12-31 | $0 | 10-K, filed 2024-02-08 | ||
| 2020-12-31 | $0 | 10-K, filed 2023-02-09 | ||
| 2019-12-31 | $0 | 10-K, filed 2021-02-11 | ||
| 2018-12-31 | $100,000,000 | 10-K, filed 2021-02-11 | ||